Preserving a balance of exclusivity and protection poses more of a challenge for biologic drugs than it does with respect to small molecule drugs. Given that biologics are derived directly from living matter or manufactured through different forms of biotechnology, they are much more complex than traditional pharmaceuticals. Therefore, even after exclusivity and patent rights expire for biologics, market entry is difficult due to significant technological barriers. Also, dramatic price decreases may not immediately follow in the wake of expired exclusivity rights. For more information, see the National Law Review’s article here.
Last Updated on April 20, 2020 by Aimed Alliance
